Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Latest News
- August 20, 2018 - Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
- July 10, 2018 - Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene’s virus-based immunotherapies TG6002 and TG1050 in Greater China
- June 4, 2018 - Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
- May 24, 2018 - Transgene Announces Upcoming Investor Meetings
